Mivision

Artificial intelligence (AI) is no longer a future possibility. It is here, it is evolving rapidly, and it is already reshaping the way medicine is practised. However, as Katrina Ronne writes, conversations about AI at the recent Australian Society of Ophthalmologists (ASO) Skills Expo, were never centred on fear.

Please be advised that the ZEISS MYO 200 is not included in the Australian Register of Therapeutic Goods (ARTG) and is therefore not available for commercial supply, promotion, or distribution in Australia. Its appearance in the OSHOW feature within the July magazine was an inadvertent error and should be disregarded. This reference does not constitute, imply, or indicate a product launch or product availability in the Australian market.

Built on more than four decades of industry experience, Opticare Academy’s e-learning platform is available to every team member, from dispensers and practice managers to optometrists and new staff.

Case Report 75-year-old Bronwyn Grech* presented to her community optometrist in 2021 with numerous large soft drusen and pigment changes in each eye, left greater than right. Additionally, in the left eye she was noted to have ELM and EZ abnormalities, drusenoid PED, and intraretinal hyper-reflective foci (IHRF) (Figures 8 and 9). Mrs Grech was pseudophakic in each eye and visual acuities were R 6/7.5; L 6/12.

Figure 1. Total1 Starter Fit Kit 2025. We all have everyday habits, from the simple to the complex; from those that serve us well to those that may be detrimental. How can these everyday habits be formed, changed or used to medical advantage? This article explores technology developments and communication opportunities that can help improve patient compliance when it comes to contact lens wear.

Two new frames – the Radar (male model), a sharp modern panto, and the Illicit Series 2 (female model), a standout unisex acetate aviator – capture fluidity in form. The striking navigator style, Gravity Series 2, earns its Fashion Frame of the Year nomination at O-SHOW26, while the innovative Phasing capsule introduces photochromic lenses in fashion-forward colours that feel unmistakably VAANYARD. Visit: vaanyard.com

Its deep tissue visualisation enables detailed assessment of retinal and choroidal structures, assisting clinicians in identifying microvascular changes at an earlier stage. Combined with advanced scanning speed and image clarity, it enhances diagnostic confidence and clinical efficiency in busy ophthalmic settings. Complementing this is the Microclear Sky whole eye imaging platform, which integrates anterior and posterior segment imaging into a unified workflow.

The findings, presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Denver, Colorado, suggested treatment benefits of Izervay increased over time.1 In the GATHER1 study, patients received Izervay every month (EM) or sham for 18 months. In the GATHER2 trial, patients were given Izervay EM or sham for 12 months, after which they were re-randomised to Izervay EM or every other month (EOM) up to 24 months.

Recent months have seen a high level of activity across Tasmania, and it has been great to see such strong and sustained engagement from members as we continue to advance key priorities for the profession. This contribution is making a tangible difference in how we advocate on your behalf. Modernising the Spectacle Assistance Scheme A major focus has been the review of the Tasmanian Spectacle Assistance Scheme.

A patient came into clinic after his driver’s licence had been refused on the basis of his Esterman visual field. When I looked at the printout, the horizontal extent appeared to be well above the Austroads cut-off for a private licence. I asked two experienced ophthalmology colleagues and a couple of optometrists what they thought. All four agreed with me. Between us, we concluded that the licensing authority had probably read the field wrong.